Objectives: Determine the cost-effectiveness of becaplermin gel for the treatment of diabetic foot ulcers (DFU) relative to good wound care (GWC) alone. MethOds: Wound surface area (WSA) reduction rates were used to predict the expected costs and outcomes of wound healing for becaplermin versus GWC cohorts over a 1-year time horizon. Changes in WSA were taken from the Phase 3 pivotal trials. The outcomes of the analysis include the average percent reduction of baseline WSA, the direct costs of DFU therapy and the cost per centimeter squared of WSA reduction. The costs for becaplermin gel and DFU patient evaluation and management were derived from standard cost references. Becaplermin utilization was calculated using the manufacturer's recommended dosing algorithm. The economic perspective was that of the payer. Costs are reported in 2013 US dollars. Results: The average WSA at baseline was 2.2 centimeters squared. At 20 weeks in the clinical study the becaplermin group demonstrated a statistically higher probability of complete wound closure compared to the GWC group (p= 0.015) at 50% versus 35%, respectively. Given the reported WSA reduction rates, becaplermin treated DFU were expected to close 100% at 27 weeks while the GWC group reached an expected 88% reduction in WSA at 52 weeks. When costs were compared by wound closure rates, the cost per 1 centimeter reduction in WSA was $1,285 in the becaplermin group compared to $3,446 in the GWC group. The total expected direct cost of DFU care across the 1-year time horizon was estimated at $6,702 in the GWC group compared to $2,827 in the becaplermin group. cOnclusiOns: DFU patients treated with becaplermin experienced better clinical outcomes than those treated with GWC alone. As a result of the improved outcomes becaplermin demonstrated economic dominance over GWC providing better outcomes at a lower direct cost.
Objectives: Determine the cost-effectiveness of becaplermin gel for the treatment of diabetic foot ulcers (DFU) relative to good wound care (GWC) alone. MethOds: Wound surface area (WSA) reduction rates were used to predict the expected costs and outcomes of wound healing for becaplermin versus GWC cohorts over a 1-year time horizon. Changes in WSA were taken from the Phase 3 pivotal trials. The outcomes of the analysis include the average percent reduction of baseline WSA, the direct costs of DFU therapy and the cost per centimeter squared of WSA reduction. The costs for becaplermin gel and DFU patient evaluation and management were derived from standard cost references. Becaplermin utilization was calculated using the manufacturer's recommended dosing algorithm. The economic perspective was that of the payer. Costs are reported in 2013 US dollars. Results: The average WSA at baseline was 2.2 centimeters squared. At 20 weeks in the clinical study the becaplermin group demonstrated a statistically higher probability of complete wound closure compared to the GWC group (p= 0.015) at 50% versus 35%, respectively. Given the reported WSA reduction rates, becaplermin treated DFU were expected to close 100% at 27 weeks while the GWC group reached an expected 88% reduction in WSA at 52 weeks. When costs were compared by wound closure rates, the cost per 1 centimeter reduction in WSA was $1,285 in the becaplermin group compared to $3,446 in the GWC group. The total expected direct cost of DFU care across the 1-year time horizon was estimated at $6,702 in the GWC group compared to $2,827 in the becaplermin group. cOnclusiOns: DFU patients treated with becaplermin experienced better clinical outcomes than those treated with GWC alone. As a result of the improved outcomes becaplermin demonstrated economic dominance over GWC providing better outcomes at a lower direct cost.
PDB68 ComParative Cost effeCtiveness of metformin-BaseD oral hyPoglyCemiC theraPy in PoPulation-BaseD DataBase
Ou H. T. , Chen M. C. , Chen Y. T.
National Cheng Kung University, Tainan, Taiwan
Objectives: Although metformin remained the mainstay of oral hypoglycemic agent (OHA), patients receiving combined OHAs significantly increased. We aimed to differentiate real-world effectiveness and economic benefit of metformin-based OHAs, from the perspective of Taiwan's National Health Insurance (NHI). MethOds: The NHI Research Database 1999 -2012 was used, which was derived from the claims of Taiwan NHI, a mandatory-enrollment and single-payment system created in 1995, covering over 99% of the population. Four metformin-based cohorts were extracted: one reference group was metformin plus sulphonylureas (Met-SU), and three comparison groups were metformin plus acarbose (Met-ACA), metformin plus thiazolidinediones (Met-TZD), and metformin plus meglitidine. By using propensity scores, each comparison cohort subject was 1:1 matched to the reference subject on demographics and comorbidity. The effectiveness outcome of interest was diabetes associated cardiovascular disease (CVD) complication risk. Only direct medical costs were included (expressed in 2012 U.S. dollars). A Markov model was applied to project lifetime effectiveness and economic outcomes, discounted at 3% per annum. Bootstrapping technique was used for assessing uncertainty in cost-effectiveness analyses. Results: The age-gender weighted average lifetime costs was $94,112.5, of which 61% was attributed to diabetic complications and the managing CVD accounted for 67% of total complication costs. The estimated CVD risk was 34%, with the highest in Met-SU and the lowest in Met-TZD (40% vs. 31%, p< .05). After a 10 year follow-up, average expenditure in Met-TZD was highest, due to higher drug acquisition price of TZD. However, over a lifetime, Met-ACA had the highest spending, most attributed to managing diabetic complications. The sensitivity analysis consistently demonstrated the cost-effectiveness of Met-TZD vs. other metformin-based therapies. cOnclusiOns: Over a lifetime, Met-TZD combination was the least expensive and most effective in lowering CVD risk. The results would inform clinical selection of "add-on" therapy in patients with inadequately controlled by metformin. Objectives: Metformin forms the first-line therapy for patients with type 2 diabetes, but the majority require treatment intensification at some stage due to the progressive nature of the disease. The 1860-LIRA-DPP4 trial showed that, at 52 weeks, liraglutide exhibited greater improvements compared with sitagliptin in HbA1c, blood pressure, serum lipids and BMI in patients with diabetes inadequately controlled on metformin monotherapy. This study compared the long-term clinical and cost implications associated with liraglutide and sitagliptin for subjects with type 2 diabetes in Spain. MethOds: Data were taken from the 1860-LIRA-DPP4 trial randomized, controlled trial at 52 weeks, in which adults with type 2 diabetes were randomly allocated to receive either 1.8mg liraglutide or 100mg sitagliptin daily in addition to metformin. Long-term (patient lifetime) projections of clinical outcomes and direct costs (2012 EUR) were made using a published and validated model of type 2 diabetes. Outcomes were discounted at 3% annually. Sensitivity analyses were performed and support the findings. Results: Liraglutide was associated with improved clinical outcomes over sitagliptin in terms of life expectancy (14.24 versus 13.87 years) and quality adjusted life-expectancy (9.24 versus 8.84 qualityadjusted life years [QALYs] ). Improved clinical outcomes were driven by improved of wound healing and amputation rates for becaplermin and non-becaplermin DFU cohorts over a 1-year time period. Outcome data used in the analysis were derived from a propensity score matched cohort of 24,898 subjects with DFU from the Curative Health Services database from 1998-2004 who were followed for 20 weeks. Primary outcomes of interest were ulcer-free weeks and rates of amputation. Costs for amputation and becaplermin gel * were derived from standard cost references and medical supply wholesalers. Total weekly costs per episode of DFU care were estimated from a large retrospective claims database. Transition probabilities for healing and amputation were derived from the aforementioned propensity score matched cohorts. Ulcer recurrence was estimated from the medical literature. Utilization for becaplermin was calculated using the manufacturer's recommended dosing algorithm. The economic perspective taken was that of the payer. Costs are reported in 2013 US dollars. Results: Overall, 2,394 (9.6%) received becaplermin. Of those who received becaplermin, 33.5% healed at 20 weeks compared to 26.5% who did not receive becaplermin (p< 0.0001). In addition, the percent of patients requiring amputation were significantly (p< 0.0001) lower in the becaplermin cohort (4.9% versus 6.4%, respectively). Patients treated with becaplermin had substantially higher ulcer-free weeks compared to non-becaplermin patients (16.1 versus 12.5 weeks, respectively). Expected annual direct costs for DFU were $20,885 for becaplermin and $23,506 for non-becaplermin. cOnclusiOns: Becaplermin was economically dominant over standard therapy, providing better outcomes at a lower cost in patients with DFU. In addition, becaplermin is more effective in wound healing and preventing amputation, thereby decreasing long-term costs for DFU. *Regranex®, Smith & Nephew Biotherapeutics, Fort Worth, Texas Objectives: Determine the cost-effectiveness of small intestinal submucosa extracellular matrix (SISEM)* relative to human fibroblast-derived dermal substitute (HF-DDS) † on wound closure for the treatment of diabetic foot ulcers (DFUs). MethOds: A 2-stage Markov model was used to predict the expected costs and outcomes of wound closure for SISEM and HF-DDS. Outcome data used in the analysis were taken from a 12-week randomized clinical trial that directly compared SISEM and HF-DDS. Twenty-six patients completed the study; 13 for SISEM and 13 for HF-DDS. The primary outcome of interest was ulcer-free days. Transition probabilities for the Markov states were estimated from the clinical trial. Resource utilization was based on the treatment regimen used in the clinical trial. Costs were derived from standard cost references and medical supply wholesalers. The economic perspective taken was that of the payer. No cost discounting was performed due to the short duration of the study. Results: Ten wounds closed in the SISEM group (77%), with an average time to closure of 36 days, while 11 wounds closed in the HF-DDS group (85%), with an average closure time of 41 days. No significant difference was found in the time to closure or in the percentage of wound closure between the two groups (p= 0.73). Expected direct costs per patient for DFU were $2,949 for SISEM and $5,282 for HF-DDS. Patients treated with HF-DDS incurred total treatment costs that were approximately 1.8 times higher than those treated with SISEM. The estimated cost per ulcer-free day was more than 1.5 times higher HF-DDS vs. SISEM. cOnclusiOns: SISEM yielded similar outcomes at a lower cost in patients with DFU. Health care providers should consider SISEM as a cost-saving alternative to HF-DDS. Objectives: Vildagliptin is a DPP-4 inhibitor available in Colombia for the treatment of diabetes mellitus as monotherapy or in combination with metformin, sulfonylureas, or insulin. Our aim was to determine the cost-effectiveness of the addition of vildagliptin to metformin, or sulfonylureas for the management of type 2 diabetes in Colombia. MethOds: We developed a hybrid decision Markov model to simulate the level of glycemic control and the health states associated with macrovascular complications (myocardial infarction, disabling stroke, and heart failure), nephropathy and death in a hypothetic cohort of patients with type 2 diabetes. Transition probabilities and utilities were derived from published trials and validated with local clinical experts. Costs were calculated based on resource use from local clinical guidelines and databases from the Ministry of Health and private institutions. The base case was developed based on the demographic characteristics of patients with type 2 diabetes in Colombia with a mean age of 59 years. The analysis was performed from the payer perspective for a time horizon of 20 years. Multivariate sensitivity analysis was performed. Results: Our results show that the addition of vildagliptine to metformine yielded an incremental effectiveness of 0.83 QALY's over the 20 years of this cohort when compared to metformine alone. The addition of vildagliptine to metformine + glimepiride combination yielded an minor increase in QALY's of only 0.27. Incremental cost for the addition of vildagliptine to metformine was $COP 3,626,000 ($1,900 USD). The incremental cost of the addition of vildagliptine to the combination of metformine was $COP 9,713,169 ($5,100 USD). The ICER for the addition of vildagliptine to metformine was $COP 4,358,350 ($2,500 USD) and to metformine + glimepiride was $ COP 35,697,647 ($18,700 USD). cOnclusiOns: The addition of vildagliptine to metformine and metformine+glimepiride is a cost-effective alternative for the treatment of diabetes type 2 in Colombia.
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comparators using Swedish-specific data, where available. Direct and indirect costs were reported in 2012 Euro [1 Euro (€ ) = 8.91 Swedish Krona] and an annual discount rate of 3% was applied on costs and effects. Results: With inclusion of indirect costs the cost-effectiveness analyses indicate that in dual therapy when compared to sitagliptin as add-on to metformin, canagliflozin appears to dominate sitagliptin with average cost savings of 718 € and an average QALY gain of 0.011 and as add-on to metformin canagliflozin appears to dominate sulfonylurea with average cost savings of 600 € and an average QALY gain of 0.063. As add-on to insulin canagliflozin appears to dominate placebo with an incremental cost saving of 3339 € and an incremental QALY of 0.054. In mono therapy canagliflozin is cost-effective compared to sulfonylurea with an incremental cost-effectiveness ratio (ICER) of 1838 € per QALY. Probabilistic analysis of the four comparisons suggests a likelihood of above 50% of canagliflozin being cost-effective. Sensitivity analyses show that canagliflozin remains cost-effective when indirect costs were not included. cOnclusiOns: Canagliflozin 100 mg and 300 mg (80/20 dose split) appears to be a cost-effective alternative to sitagliptin and glimepiride in dual therapy as add-on to metformin. Adding canagliflozin to insulin will be cost-effective compared with placebo. Canagliflozin is a cost-effective alternative to sulfonylurea in mono therapy. Objectives: Point-of-care testing of blood glucose (BG-POCT) is essential for safe insulin infusion in critically ill patients. Costs associated with BG-POCT are considered substantial, especially when more frequent monitoring is needed as with strict glucose control aiming for lower BG-levels. The objective of this study is to estimate the incremental cost-effectiveness of a strict BG-POCT guideline versus a loose guideline, from a hospital perspective. MethOds: This is a secondary analysis of a guideline implementation project aiming for normal BG-levels in three intensive care units in The Netherlands [1] . A Markov model including health states 'target glucose', 'hyperglycemia', 'hypoglycemia', and hospital death was developed to compare expected costs, number of patients within target and number of life years saved before and after guideline implementation. Results: The analysis included 1.321 and 2.175 patients 12 and 24 months before and after implementation of the guideline, respectively. The number of BG-POCT increased from 4.2 [2.6 -6.7] to 8.7 [4.1 -11.2] per patient per day. Costs for BG-POCT increased with 72%. When taking total hospital costs and clinical effects into account, implementation of the strict glycemic control guideline reduces hospital costs with € 134 during total inpatient stay, as patients spend less time in hypo/hyperglycemic events and had shorter stays in ICU and hospital (-0.5 and -1.1 day, respectively). This translates into expected cost savings of € 13 per additional patient in target glucose and € 10 per additional life year saved. The model outcomes are most sensitive to changes in ICU length of stay. cOnclusiOns: This health-economic analysis shows that additional costs of BG-POCT with implementation of a strict glucose control guideline are offset against savings generated by reduced hypo/hyperglycemic events and length of stay in ICU and hospital. Beijing, China, 2 Ruijin Hospital (Luwan), Shanghai, China, 3 Novonordisk(China) Pharmaceuticals Co., Ltd., Beijing, China, 4 Peking University, Beijing, China Objectives: To evaluate long-term cost-effectiveness of switching from human premix insulin to biphasic insulin aspart (BIAsp 30) in people with type 2 diabetes mellitus (T2DM) in China. MethOds: The previously published and validated IMS Core Diabetes Model was used to project life expectancy, quality-adjusted life years (QALYs) and total direct medical costs over 30 years from a societal perspective. Patient characteristics and treatment effects were obtained from Chinese subgroup (n= 1191) in the A 1 chieve ® observational study. After treatment with BIAsp 30 over 24 weeks, patients' HbA 1c decreased by 1.6%, rate of major and minor hypoglycaemia decreased by 0.51 and 4.32 events per patient-year respectively. Treatment costs were based on insulin doses (35.8 IU daily for human premix insulin and 36.1 IU for BIAsp 30) and market retail prices in China. Management (concomitant medications, screening programmes, etc) and complication costs were obtained from Chinese published data in 2011 and adjusted to the price level of 2012 with the consumer price index. Costs and life years were discounted at 3% annually. One-way sensitivity analysis was performed. Results: Switching to BIAsp 30 from human premix insulin was projected to reduce incidence of most diabetes-related complications, increase life expectancy by 0.732 years (13.457 vs 12.725 ) and improve qualityadjusted life years by 1.032 QALYs (9.487 vs 8.455) per patient. Although treatment and management costs increased by Chinese Yuan (CNY) 14,712 (52,329 vs. 37,617) and 1,857 (39,821vs. 37,964) respectively, complication costs reduced by CNY 96, 198 (104, 752 vs. 200, 950) ; switching to BIAsp 30 from human premix insulin was associated with reduced total direct medical cost of CNY 79, 628 (196, 902 vs. 276, 530) . Sensitivity analyses demonstrated robustness of the results. cOnclusiOns: Switching to BIAsp 30 from human premix insulin was associated with improvements in life expectancy and QALYs, and was a cost-saving treatment strategy for people with T2DM in China. glycemic control, leading to a reduced incidence of diabetes-related complications, including renal disease, cardiovascular disease, ophthalmic and diabetic foot complications. Liraglutide was associated with increased direct costs (EUR 56, 628 versus EUR 52, 450) , driven by the acquisition cost of liraglutide. However, this was partially offset by the reduced cost of treating diabetes-related complications. Based on these estimates, liraglutide was associated with an incremental cost-effectiveness ratio of EUR 10,436 per QALY gained versus sitagliptin. cOnclusiOns: Liraglutide 1.8mg was projected to improve clinical outcomes over sitagliptin as a result of reduced incidence of diabetes-related complications. Liraglutide is likely to be cost-effective from a health care payer perspective in Spain. Objectives: Glucagon-like peptide-1 receptor agonists (GLP-1RAs), such as exenatide once weekly (EQW) and liraglutide (LIRA), are FDA-approved as treatment for type 2 diabetes mellitus (T2DM). Head-to-head studies and meta-analyses of these agents have reached different conclusions about their relative effectiveness. MethOds: We developed a decision-analytic model to evaluate the likely incremental cost-effectiveness of EQW versus LIRA 1.8 mg in T2DM patients, with effectiveness measured as reduction in glycated hemoglobin (HbA1c). The model structure tracks change in HbA1c and direct medical expenditure (drug, needle, adverse events [AEs]) over a 26-week time horizon, and allows patients to discontinue treatment due to AEs (nausea, diarrhea, vomiting, constipation, dyspepsia) after 1 or 3 months of therapy. Patients discontinuing treatment are assumed to return to their baseline HbA1c. We compared the outcomes (cost per 1% and 0.2% reduction in HbA1c) of models populated with clinical data from a head-to-head 26-week randomized, controlled trial (DURATION-6) and a meta-analysis conducted by Scott and colleagues (2012) . Drug costs and other utilization costs were based on wholesale acquisition costs and published sources. Results: For the base case, the projected total 6-month cost of EQW versus LIRA was $2,444 and $3,054, respectively. Using data from DURATION-6 and meta-analysis, compared with EQW, LIRA had a projected incremental cost per 1% reduction in HbA1c (ICER) of $3,262 and $18,578 over a 6-month time horizon, respectively. Compared with EQW, the projected 6-month cost per 0.2% reduction in HbA1c for LIRA was $652 and $3,716 based on data from DURATION-6 and meta-analysis, respectively. cOnclusiOns: The projected cost per 1% reduction in HbA1c was lower with EQW than liraglutide 1.8 mg at 6 months. The difference in projected cost per HbA1c reduction varies significantly depending on the trial-based data sources used. Real-world data are needed to resolve the current uncertainties. Objectives: To evaluate the efficiency, in terms of incremental cost-effectiveness ratios (ICER), of human chorionic gonadotropin (hCG) and human gonadotropins, drugs used for male infertility due to hormonal disorder hypogonadotropic hypogonadism (HH), whose female partner has or doesn't have infertility problems, in the context of an assisted reproduction program. MethOds: Two different decision trees were developed to assess ICER of hCG and human gonadotropins. Firstly, hCG was compared to no treatment; secondly, human gonadotropins in combination with hCG were compared to hCG used alone. Effectiveness was measured as pregnancy and spermatogenesis respectively. Data were obtained from clinical studies, as well as efficacy of medical procedures. The proportion of couples, who needed fertility procedures, was determined according to experts' opinion. A ministry of health perspective was taken. Costs of medications were based on acquisition costs in 2012 Canadian dollars. Costs of medical procedures, as intrauterine insemination (IUI), in vitro fertilisation (IVF) and intra cytoplasmic sperm injection (ICSI) were based on 2012 fees of Québec's physicians. The time horizons adopted were based on the durations of drug treatment in clinical studies. Results: The use of hCG in comparison with no treatment is cost-effective with an ICER of 20,915$CAN per man with HH for whom the partner got pregnant. Determinist sensitivity analyses showed that the ratio is more sensitive to the probability to use IVF or ICSI. In the second comparison, treatment with human gonadotropins is cost-effective with an ICER of 25,076$CAN per man that obtained spermatogenesis. Drug dosage is the element for which the ICER is more sensitive in the univariate determinist sensitivity analyses. cOnclusiOns: Human gonadotropins and hCG are cost-effective for the treatment of men with HH. They can be reimbursed in the drug program for this indication with some restrictions about the duration of treatment. Objectives: To evaluate the cost-effectiveness of canagliflozin in dual therapy as add-on to metformin compared to sitagliptin and glimepiride, as add on to insulin (plus metformin) and in mono therapy compared to sulfonylurea in the Swedish setting from a societal perspective. MethOds: The IMS CORE Diabetes Model was used to evaluate the cost-effectiveness of canagliflozin (using a weighted average of 80/20 for the 100 mg and 300 mg dosage respectively) versus the aforementioned
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